Relugolix
Back to searchMolecule Structure
Scientific Name
Relugolix
Description of the Drug
Relugolix is an oral GnRH receptor antagonist for androgen deprivation therapy in the treatment of advanced prostate cancer.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11853
http://www.drugbank.ca/drugs/DB11853
Brand Name(s)
Orgovyx
Company Owner(s)
Myovant Sciences Gmbh
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Gonadotropin-releasing hormone receptor | SINGLE PROTEIN | ANTAGONIST | CHEMBL1855 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL778416 |
| Human Metabolome Database | HMDB0304861 |
| DrugBank | DB11853 |
| PubChem: Thomson Pharma | 15360452 |
| PubChem | 10348973 |
| BindingDB | 50347982 |
| EPA CompTox Dashboard | DTXSID40224167 |
| DrugCentral | 5432 |
| ChemicalBook | CB42658205 |
| Guide to Pharmacology | 5586 |
| ZINC | ZINC000043206033 |
